Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

ASPR's Response to COVID-19

Monoclonal Antibody Therapeutics: What infusion centers, healthcare providers, and patients need to know


In response to the 2019 Novel Coronavirus outbreak, the federal government is taking steps to protect the American people. Within the U.S. Department of Health and Human Services, the Office of the Assistant Secretary for Preparedness and Response is working with our partners to explore the development of new medical countermeasures and take other actions to enhance health security.

Medical Countermeasure Development and Acquisition




Strategic National Stockpile



 

COVID-19 Health Care System Response



COVID-19 Supplemental Funding »


Legal Authorities

 



​Public Health Emergency Declarations »
Waiver or Modification of Requirements Under
Section 1135 of the Social Security Act »

Public Readiness and Emergency Preparedness Act »
Emergency Use Authorizations »


Technical Assistance, Training, and Resources




ASPR TRACIE-Developed Infectious Disease Resources »


ASPR’s COVID-19 Response from the Field







ASPR’s COVID-19 Response by the Numbers


81
COVID-19 medical
countermeasures
supported by BARDA

16K+
tons of cargo shipped by
SNS to support U.S. repatriation
efforts and state PPE needs​
20
Emergency Use Authorizations
issued for BARDA-Supported
SARS CoV-2 Tests​


  • This page last reviewed: September 20, 2021